Nurix Story

<div class='circular--portrait' style='background:#8B008B;color: #ffffff;font-size:4em;'>NT</div>
NRIX -- USA Stock  

USD 44.63  1.98  4.64%

Nurix Therapeutics is scheduled to announce its earnings today. The stock experiences an active downward rally. While many of us are getting excited about healthcare space, we are going to break down the feasibility of acquiring Nurix. What exactly are Nurix Therapeutics shareholders getting in November?
Published over three months ago
View all stories for Nurix Therapeutics | View All Stories
Should you trust Nurix Therapeutics (NASDAQ:NRIX) current analyst consensus?
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Nurix suggests not a very effective usage of assets in October.
What is the right price you would pay to acquire a share of Nurix Therapeutics? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

How important is Nurix Therapeutics's Liquidity

Nurix Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Nurix Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Nurix Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Nurix Therapeutics's total debt and its cash.

How Nurix utilizes its cash?

To perform a cash flow analysis of Nurix Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Nurix Therapeutics is receiving and how much cash it distributes out in a given period. The Nurix Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Exercise or conversion by Hansen Gwenn of 12000 shares of Nurix Therapeutics subject to Rule 16b-3

Legal trades by Nurix Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Nurix insider trading alert for exercise of employee stock option (right to buy) by Hansen Gwenn, Chief Scientific Officer, on 1st of December 2020. This event was filed by Nurix Therapeutics Inc with SEC on 2020-12-01. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Nurix a risky opportunity?

Let's check the volatility. Nurix is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Nurix (NASDAQ:NRIX) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. acquiring a share of a Nurix Therapeutics stock makes you a part-owner of that company.

Nurix Therapeutics Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Nurix Therapeutics. The Nurix consensus assessment is calculated by taking the average estimates from all of the analysts covering Nurix Therapeutics

Strong Buy
Strong Buy375.0
Strong Sell00.0

Our take on Nurix Therapeutics to rebound

Current coefficient of variation is at 517.61. Nurix Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Nurix Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Nurix Therapeutics volatility.

Our Conclusion on Nurix Therapeutics

While other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Nurix Therapeutics may offer a potential longer-term growth to investors. To conclude, as of the 2nd of October 2020, our analysis shows that Nurix Therapeutics almost neglects market trends. The company is fairly valued and projects average chance of distress for the next 2 years. Our concluding 30 days buy vs. sell advice on the company is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Nurix Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to